跨膜蛋白
免疫原性
信号转导
表皮生长因子受体
癌症研究
计算生物学
抗体
生物
化学
受体
细胞生物学
生物化学
免疫学
作者
Long Wang,Gengyuan Zhang,Long Qin,Hui-Li Ye,Yan Wang,Bo Long,Jiao Zhang
出处
期刊:Recent Patents on Anti-cancer Drug Discovery
[Bentham Science]
日期:2020-12-07
卷期号:15 (3): 200-211
被引量:6
标识
DOI:10.2174/1574892815666200904111728
摘要
Background: Epidermal Growth Factor Receptor (EGFR) and members of its homologous protein family mediate transmembrane signal transduction by binding to a specific ligand, which leads to regulated cell growth, differentiation, proliferation and metastasis. With the development and application of Genetically Engineered Antibodies (GEAs), Nanobodies (Nbs) constitute a new research hot spot in many diseases. A Nb is characterized by its low molecular weight, deep tissue penetration, good solubility and high antigen-binding affinity, the anti-EGFR Nbs are of significance for the diagnosis and treatment of EGFR-positive tumours. Objective: This review aims to provide a comprehensive overview of the information about the molecular structure of EGFR and its transmembrane signal transduction mechanism, and discuss the anti-EGFR-Nbs influence on the diagnosis and treatment of solid tumours. Methods: Data were obtained from PubMed, Embase and Web of Science. All patents are searched from the following websites: the World Intellectual Property Organization (WIPO®), the United States Patent Trademark Office (USPTO®) and Google Patents. Results: EGFR is a key target for regulating transmembrane signaling. The anti-EGFR-Nbs for targeted drugs could effectively improve the diagnosis and treatment of solid tumours. Conclusion: EGFR plays a role in transmembrane signal transduction. The Nbs, especially anti- EGFR-Nbs, have shown effectiveness in the diagnosis and treatment of solid tumours. How to increase the affinity of Nb and reduce its immunogenicity remain a great challenge.
科研通智能强力驱动
Strongly Powered by AbleSci AI